Papillary thyroid cancer (PTC) generally has a good prognosis, with 5-year relative survival rates of 99% for regional cancer that has spread to the lymph nodes. PTC is the most common type of thyroid ...

“We are excited to see this strong survival benefit for head and neck cancer patients with such cold tumors. Combining these two complementary immunotherapies has led to a 7-fold increase in response ...

Buparlisib plus paclitaxel did not improve overall survival compared to paclitaxel alone in PD-1/PD-L1-pretreated recurrent/metastatic HNSCC patients. The combination showed a higher overall response ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant combination immunotherapy regimens produced higher pathologic response rates than monotherapy in a ...

Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.

After decades of decline, rates of cervical cancer within Canada have plateaued, according to the Canadian Cancer Society — a ...

The growth of the Head and Neck Cancer Drugs/Therapeutics Market is primarily driven by rising global incidence rates, increasing adoption of advanced immunotherapies, and continuous innovation ...